The ImmunoVerse™
The ImmunoVerse™
Podcast Description
The ImmunoVerse™ is a monthly podcast exploring the past, present and future of immunotherapy and delving into every intricacy of the body's immune system. Hosted by Moffitt Cancer Center President and CEO, Dr. Patrick Hwu, each episode highlights the trailblazing visionaries who are pushing boundaries in this ever-evolving, world-changing field.
Podcast Insights
Content Themes
The podcast explores the intricacies of the immune system and immunotherapy, with episodes delving into historical milestones like the Origins of Cancer Immunotherapy featuring Dr. Steven Rosenberg, alongside discussions about current advances in cancer treatment and predictions for future innovations in the field.
The ImmunoVerse™ is a monthly podcast exploring the past, present and future of immunotherapy and delving into every intricacy of the body’s immune system. Hosted by Moffitt Cancer Center President and CEO, Dr. Patrick Hwu, each episode highlights the trailblazing visionaries who are pushing boundaries in this ever-evolving, world-changing field.
Dr. Patrick Hwu welcomes Dr. Fred Locke, chair of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center. Dr. Locke shares his personal and professional journey into CAR T-cell therapy, shaped in part by his own father’s cancer battle. A leader in pivotal clinical trials, Dr. Locke explains how engineered T cells are transforming lymphoma treatment — offering durable, sometimes curative responses. He discusses the science behind CAR T-cell manufacturing, trial design and its growing applicatio to diseases like multiple myeloma, along with future innovations in cellular immunotherapy.
What You’ll Learn from Dr. Locke
How a personal family experience inspired Dr. Locke’s passion for immunotherapy
The story behind pivotal CAR T clinical trials (ZUMA-1 and ZUMA-7) and their FDA approvals
What makes CAR T therapy so effective in blood cancers — and the challenges with solid tumors
Innovative approaches on the horizon: donor-derived CAR Ts, TIL therapy, and engineered TCR therapies
Why diet, exercise, and prehabilitation may improve immune cell therapy outcomes
How Moffitt is scaling CAR T for outpatient treatment and community hospital access
Access more show notes, links and transcript here: https://www.moffitt.org/about-moffitt/podcasts/immunoverse/future-of-cellular-treatments/
Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.